Abstract
Multiple myeloma (MM) is an incurable clonal plasma cell malignancy that imposes a substantial global health burden. This study evaluates the global, regional, and national burden of MM by sex, age, and Socio-demographic Index (SDI) from 1990 to 2021, identifies causal risk factors, and projects temporal trends through 2050. Utilizing data from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021, we employed Joinpoint regression for trend analysis, two-sample Mendelian randomization (MR) to establish causal relationships between weight-related factors and MM, and Bayesian age-period-cohort (BAPC) models for future projections. In 2021, the global age-standardized prevalence rate (ASPR) was 4.65 per 100,000 people. The burden was highest in high-SDI regions and among elderly populations. MR analysis confirmed high body mass index (BMI) and other obesity metrics as causal risk factors. While global incidence rates are predicted to decrease slightly by 2050, a concerning increase is projected within the 20–69 age group, necessitating targeted prevention strategies.
Introduction
Multiple myeloma (MM) is the second most common hematological malignancy worldwide. Characterized by the uncontrolled proliferation of plasma cells in the bone marrow, it leads to bone destruction, renal failure, and immune deficiency. Despite significant therapeutic advancements that have extended survival, MM remains largely incurable. As the global population ages and lifestyle-related risk factors—particularly obesity—become more prevalent, understanding the shifting epidemiological landscape of MM is critical for public health planning. This study provides a comprehensive analysis of MM burden over three decades and offers a data-driven forecast of the disease's trajectory over the next 30 years.
Methods
This research utilized a multi-faceted analytical framework based on the GBD 2021 dataset, which covers 204 countries and territories.
- Epidemiological Metrics: We analyzed prevalence, incidence, mortality, and disability-adjusted life years (DALYs).
- Trend Analysis: Joinpoint regression was used to calculate the Average Annual Percent Change (AAPC), identifying significant shifts in disease rates over time.
- Causal Inference: To move beyond simple correlation, we conducted a two-sample Mendelian randomization (MR) analysis using genetic variants from the OpenGWAS Project. This allowed us to assess the causal impact of BMI, waist circumference, and obesity on MM risk.
- Forecasting: Future incidence rates were projected through 2050 using the Bayesian age-period-cohort (BAPC) model, which accounts for historical trends in age and time periods.
Results
Global and Regional Trends (1990–2021)
The global burden of MM has expanded dramatically. Between 1990 and 2021, the number of prevalent cases increased by 218.20%, reaching approximately 394,482 cases. In 2021, the age-standardized mortality rate (ASMR) was 1.40 per 100,000 people.
The distribution of MM is heavily influenced by socio-economic development. The highest age-standardized rates (ASRs) were consistently found in high-SDI regions, such as Australasia and North America. Specifically, Monaco and the Bahamas reported the highest age-standardized incidence, DALY, and mortality rates in 2021. Conversely, the lowest rates were observed in low-SDI regions, including parts of Oceania and Africa.
Demographic Disparities
Age and sex remain primary determinants of MM burden. Rates peaked in the elderly population (70+ years) and were significantly higher in males than in females across nearly all geographic regions. However, middle-SDI regions showed the most rapid upward trends in disease burden, suggesting that as these nations undergo economic transitions, their cancer profiles are increasingly resembling those of high-income countries.
Causal Risk Factors
One of the study's most significant findings is the causal link between metabolic health and MM. GBD 2021 data identified high BMI as a major risk factor, contributing to nearly 8% of global MM mortality. The MR analysis further solidified this, showing that BMI, waist circumference, hip circumference, and various classes of obesity are causal drivers of the disease. This relationship may be mediated by the production of interleukin-6 in adipose tissue, which promotes the growth of myeloma cells.
Projections to 2050
While the overall global age-standardized incidence rate is predicted to see a slight decline by 2050, the BAPC model reveals a troubling shift in age-specific demographics. The incidence of MM is projected to increase among individuals aged 20–69. This suggests that the disease may increasingly affect the working-age population, potentially due to the rising global prevalence of obesity and metabolic syndrome in younger cohorts.
Discussion and Conclusion
Multiple myeloma remains a significant and growing public health challenge. The massive increase in prevalence over the last 30 years reflects both an aging global population and improved diagnostic capabilities in high-SDI regions. However, the emerging burden in middle-SDI countries and the projected rise in younger age groups signal a need for a shift in prevention strategies.
The confirmation of obesity as a causal risk factor provides a clear target for intervention. Public health initiatives focused on weight management and metabolic health could significantly reduce the future incidence of MM. Furthermore, the disparity in burden between high and low SDI regions highlights the need for improved healthcare infrastructure and cancer registries in developing nations to ensure early diagnosis and equitable access to treatment.
In conclusion, while medical treatments for MM continue to evolve, the rising global burden—particularly among younger adults—demands a renewed focus on primary prevention and targeted screening for high-risk populations.
Summary updated